S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

被引：0

作者：

Nikolaus B Wagner

Andrea Forschner

Ulrike Leiter

Claus Garbe

Thomas K Eigentler

机构：

[1] University Hospital Tuebingen,Department of Dermatology

来源：

British Journal of Cancer | 2018年 / 119卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：339 / 346

页数：7

共 50 条

[41] Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Wei, Spencer C.
Levine, Jacob H.
Cogdill, Alexandria P.
Zhao, Yang
Anang, Nana-Ama A. S.
Andrews, Miles C.
Sharma, Padmanee
Wang, Jing
Wargo, Jennifer A.
Pe'er, Dana
Allison, James P.
CELL, 2017, 170 (06) : 1120 - 1133
[42] Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Patel, Sandip P.
Cano-Linson, Eleanor
Chae, Young Kwang
Schokrpur, Shiruyeh
Lao, Christopher D.
Powers, Benjamin C.
Victor, Adrienne I.
Onitilo, Adedayo A.
Shin, Sarah
Takebe, Naoko
Threlkel, Sara
Mcleod, Christine M.
Chen, Helen X.
Sharon, Elad
Othus, Megan
Ryan, Christopher W.
Blanke, Charles D.
Kurzrock, Razelle
NPJ PRECISION ONCOLOGY, 2025, 9 (01)
[43] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
Holmes, Zachary
Courtney, Ashling
Hiong, Alison
BMJ CASE REPORTS, 2022, 15 (08)
[44] Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
Rozeman, E. A.
Moritz, R.
Wilgenhof, S.
van Thienen, J. V.
Haanen, J. B. A. G.
van den Heuvel, M.
Blank, C. U.
Van Rossum, H.
ANNALS OF ONCOLOGY, 2019, 30
[45] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Afzal, Muhammad Zubair
Mercado, Rima R.
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[46] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
Afzal, Muhammad Z.
Shirai, Keisuke
MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
[47] Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
Hassel, Jessica C.
Heinzerling, Lucie
Aberle, Jens
Baehr, Oliver
Eigentler, Thomas K.
Grimm, Marc-Oliver
Gruenwald, Victor
Leipe, Jan
Reinmuth, Niels
Tietze, Julia K.
Trojan, Joerg
Zimmer, Lisa
Gutzmer, Ralf
CANCER TREATMENT REVIEWS, 2017, 57 : 36 - 49
[48] SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer
Patel, Sandip P.
Guadarrama, Elizabeth
Chae, Young Kwang
Dennis, Michael J.
Powers, Benjamin C.
Liao, Chih-Yi
Ferri, William A.
George, Thomas J.
Sharon, Elad
Ryan, Christopher W.
Othus, Megan
Lopez, Gabby
Blanke, Charles D.
Kurzrock, Razelle
CANCER, 2024, 130 (17) : 2918 - 2927
[49] Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, Rituparna
Verma, Rakesh
Sznol, Mario
Boddupalli, Chandra Sekhar
Gettinger, Scott N.
Kluger, Harriet
Callahan, Margaret
Wolchok, Jedd D.
Halaban, Ruth
Dhodapkar, Madhav V.
Dhodapkar, Kavita M.
JOURNAL OF IMMUNOLOGY, 2015, 194 (03): : 950 - 959
[50] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089

← 1 2 3 4 5 →